Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

IS-741 (Ishihara Sangyo).

¹Surgical and Gastroenterological Department, University of Verona, Hospital GB Rossi, Verona, Italy. Claudio.Bassi@univr.it

Current Opinion in Investigational Drugs (London, England : 2000)

|September 22, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab-bevacizumab resistance and worse survival in advanced hepatocarcinoma.

ESMO open·2025

Same author

A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing.

ESMO open·2023

Same author

Correction: Prophylactic abdominal drainage or no drainage after distal pancreatectomy (PANDORINA): a study protocol of a binational multicenter randomized controlled trial.

Trials·2023

Same author

Prophylactic abdominal drainage or no drainage after distal pancreatectomy (PANDORINA): a binational multicenter randomized controlled trial.

Trials·2022

Same author

Progression from biochemical leak to pancreatic fistula after distal pancreatectomy. Don't cry over spilt amylase.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2022

Same author

The faith of non-surveilled pancreatic cysts: a bicentric retrospective study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2021

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

IS-741, a phospholipase A2 (PLA2) inhibitor, shows promise in treating pancreatitis. Studies indicate it may prevent lung injury associated with pancreatitis, advancing to Phase II trials.

Area of Science:

Pharmacology
Gastroenterology
Pulmonology

Background:

Pancreatitis is a serious condition with potential complications like lung injury.
Phospholipase A2 (PLA2) plays a role in the inflammatory processes of pancreatitis.
IS-741 is an investigational drug targeting PLA2.

Purpose of the Study:

To evaluate the potential of IS-741 as a treatment for pancreatitis.
To assess the efficacy of IS-741 in preventing pancreatitis-associated lung injury.

Main Methods:

IS-741 is a phospholipase A2 (PLA2) inhibitor.
Development is ongoing by Ishihara Sangyo Kaisha and Sumitomo.
Phase II clinical trials are underway for acute pancreatitis.
Efficacy in preventing pancreatitis-associated lung injury was studied in an animal model.

Related Experiment Videos

Main Results:

IS-741 is under development as a pancreatitis treatment.
The drug is in Phase II trials for acute pancreatitis.
IS-741 demonstrated preventative effects against pancreatitis-associated lung injury in an animal model.

Conclusions:

IS-741 is a promising therapeutic candidate for pancreatitis.
Further clinical trials are warranted to confirm its efficacy and safety in humans.
The drug may offer a novel approach to managing pancreatitis complications.